Health Economics›Neuroendocrine tumor›All lines of therapy

All lines of therapy

Neuroendocrine tumor · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lutetium Lu 177 dotatate and Octreotide LAR Variant #02	—	R 83 977	56d	—	~48.0 mo	—	—	3
Everolimus and Octreotide Variant #01	—	R 37 172	28d	~16.4 mo	—	~18	~R 669 096 PFS proxy · indirect	1
Octreotide LAR monotherapy Variant #01	—	R 27 992	28d	5.8 mo	84.7 mo	7	R 195 945 PFS proxy	2
Lanreotide monotherapy Variant #01	—	R 20 067	28d	—	—	—	—	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~11.0 mo	—	~12	~R 220 316 PFS proxy · indirect	2
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~4.0 mo	~16.3 mo	~5	~R 40 764 PFS proxy · indirect	10
Octreotide and Interferon alfa Variant #01	—	R 7 732	7d	—	—	—	—	—
Octreotide monotherapy Variant #04	—	R 5 799	—	—	—	—	—	—
Capecitabine and Temozolomide Variant #01	—	R 5 399	28d	—	—	—	—	—
Lanreotide and Interferon alfa-2b Variant #01	—	R 5 017	7d	—	—	—	—	—
Doxorubicin and Fluorouracil Variant #01	—	R 658	35d	—	15.7 mo	—	—	—
Fluorouracil and Streptozocin Variant #01 Partial	—	R 275	42d	—	24.3 mo	—	—	—
Lanreotide LAR monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Placebo Partial	—	—	—	3.9 mo	—	—	—	2
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~15	—	2

15 of 15 regimens shown